| Literature DB >> 18628509 |
Madhukiran H Murthy1, Michael E Olson2, Robert W Wickert2, Paul D Fey2, Ziba Jalali1.
Abstract
Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in mprF, resulting in a T345A substitution, associated with non-susceptibility to daptomycin.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18628509 DOI： 10.1099/jmm.0.2008/000588-0
Source DB: PubMed Journal: J Med Microbiol ISSN： 0022-2615 Impact factor: 2.472